European recommendations for short-term surveillance of health problems in childhood, adolescent and young adult cancer survivors from the end of treatment to 5 years after diagnosis: a PanCare guideline

\ua9 The Author(s) 2023. Purpose: Childhood, adolescent and young adult (CAYA) cancer survivors require ongoing surveillance for health problems from the end of cancer treatment throughout their lives. There is a lack of evidence-based guidelines on optimal surveillance strategies for the period from the end of treatment to 5 years after diagnosis. We aimed to address this gap by developing recommendations for short-term surveillance of health problems based on existing long-term follow-up (LTFU) care guidelines. Methods: The guideline working group, consisting of healthcare professionals, parents and survivor representatives from 10 countries, worked together to identify relevant health problems that may occur in survivors between the end of treatment and 5 years after diagnosis and to develop recommendations for short-term surveillance of health problems. The recommendations were drawn from existing LTFU guidelines and adapted where necessary based on clinical expertise. Results: The working group developed 44 recommendations for short-term surveillance of health problems, which were divided into four categories based on the level of surveillance required: awareness only (n = 11), awareness, history and/or physical examination without surveillance test (n = 15), awareness, history and/or physical examination with potential surveillance test (n = 1) and awareness, history and/or physical examination with surveillance test (n = 17). Conclusion: The development of a guideline for short-term surveillance of health problems fills a critical gap in survivorship care for CAYA cancer survivors, providing much-needed support immediately after treatment up to 5 years after diagnosis. Implications for Cancer Survivors. This guideline will support healthcare professionals to provide appropriate follow-up care and improve the quality of life of CAYA cancer survivors

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

Eosinophilic asthma is characterized by high eosinophil levels in induced sputum and peripheral blood. Elevated airway eosinophil counts can be detected in more than 50% of asthmatics and associated with more symptoms, frequent exacerbations, and greater airflow limitation.1 Increased blood eosinophils (BEs) also predict a greater response to new biological therapies (mepolizumab, reslizumab).2 Higher pretreatment BE levels are also related to a better response to omalizumab,3 which reduces BE, fractional exhaled nitric oxide (FENO), serum periostin, and exacerbations.4,5 Therefore, a higher effect on eosinophil count reduction may lead to greater clinical improvements. Accordingly, if omalizumab response is eosinophilic dependent, it might be reduced in subjects with persistent high BE counts after antiIgE therapy